APO-GOCopy

• DRUGBANK - Apomorphine
• indication:

  For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.

• pharmacology:

• mechanism:

  The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson's disease. In particular, apomorphine attenuates the motor deficits induced by lesions in the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates.

• toxicity:

  LD<sub>50</sub>=0.6 mmoles/kg (mice, intraperitoneal)

• absorprion:

  100% following subcutaneous administration

• halflife:

  40 minutes (range 30 - 60 minutes)

• roouteelimination:

• volumedistribution:

  * 123 to 404 L

• clearance:

  * 223 L/hr